Seer

Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr. and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Seer reports strong Q4 earnings, eyes revenue growth in 2023

Seer's Q4 2022 earnings reflect robust growth, driven by product sales and service projects. While challenges persist in China market access, the company is poised for revenue growth in 2023 through consumables and service contracts.

Seer (SEER) reports strong Q1 revenue growth and technology validation

Seer's Q1 performance showed revenue growth and a focus on disciplined expense management for financial strength.
The company's emphasis on Proteograph technology and customer validation positions it well for future growth.
While facing challenges in sales cycles and market opportunities, Seer is leveraging strategic initiatives for growth.

Seer reports revenue growth amidst challenges, focuses on strategic initiatives

Seer's Q2 performance showed revenue growth but faced a net loss due to operating expenses, prompting strategic cost management and sales cycle improvements.
Strengths lie in product expansion, strategic collaborations, and a focus on consumable margins, positioning Seer well in the proteomics market.
Challenges in adoption and cost alignment require focused efforts, while opportunities in customer engagement and strategic programs offer growth potential.

Seer reports Q3 revenue growth amidst macro challenges and partnerships

Seer's Q3 performance showed revenue growth but with a net loss, ending the quarter with a strong cash position. The company faces challenges from macroeconomic uncertainty impacting revenue and sales cycles. Seer's initiatives and partnerships present opportunities for growth and market adoption.

Seer reports revenue growth in 2023, eyes innovation for 2024

Seer's 2023 performance showed revenue growth and cost management improvements, ending the year well-funded.
Strong demand for technology and programs, coupled with a focus on innovation and evidence, positions Seer for growth.
Challenges in China and Europe markets require strategic navigation, while opportunities lie in revenue growth and technology advancements.

Seer reports Q1 revenue of $3.1M, focuses on innovation and cost-saving

Seer's Q1 2024 performance reflected revenue of $3.1 million, with cost-saving measures leading to reduced operating expenses. The company faces challenges in revenue growth due to slow platform adoption but is leveraging strengths in innovative technology and research support programs. Strategic initiatives like market share repurchase and global expansion present opportunities for future growth.

Seer reports revenue growth and strategic partnerships amid profitability challenges

Seer's Q3 performance reflects revenue growth and strategic collaborations despite financial losses.
The company's strong cash reserves and partnerships signal resilience and potential for market expansion.
While facing profitability challenges, Seer's innovative technology and market demand offer growth opportunities.
Navigating market uncertainties and optimizing financial performance are key focus areas for Seer.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Seer, Inc. (NASDAQ: SEER) resulting from allegations that Seer may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Seer securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law

EQUITY ALERT: Rosen Law Firm Encourages Seer, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – SEER

REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Third Quarter Financial Results on November 9, 2021

The proteomics market size was $21 billion in 2019 and is estimated to increase to $64 billion in 2024 (growing annually at 15%), larger than the genomics market. The company's proteomics diagnostics technology is Proteograph, an integrated solution consisting of consumables, automation instrument and software, which was licensed from Harvard.

Seer: First Pick In Proteomics Portfolio

REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.

Seer to Present at the Morgan Stanley Global Healthcare Conference

Seer, Inc.'s (SEER) CEO Omid Farokhzad on Q2 2021 Results - Earnings Call Transcript

Expanded installed base and booked initial revenue for Proteograph Product Suite Expanded installed base and booked initial revenue for Proteograph Product Suite

Seer Reports Second Quarter 2021 Financial Results

REDWOOD CITY, Calif. and BEIJING, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has signed an exclusive distribution agreement with Enlight Medical , a leading company in the development, production and distribution of innovative medical diagnostics and therapeutic devices in China. The agreement accelerates commercial availability of Seer's Proteograph Product Suite to the rapidly expanding Chinese life sciences and clinical markets.

Seer Bio Partners with Enlight Medical to Commercialize the Proteograph™ Product Suite in China

Airbnb

Disney

SoFi Technologies

Wish

Of a dozen firms that reported earnings before markets opened on Wednesday, eight beat estimates and four missed.

Earnings Previews: Airbnb, ContextLogic, Disney, Seer, SoFi

REDWOOD CITY, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the second quarter 2021 after market close on Thursday, August 12, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Second Quarter Financial Results on August 12, 2021

Biodesix

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitled “A New Era in Precision Medicine - Uncovering the Depth & Breadth of the Plasma Proteome with Novel Proteomi

Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer

Seer, Inc. (SEER) CEO Omid Farokhzad on Q1 2021 Results - Earnings Call Transcript

Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers

Seer Reports First Quarter 2021 Financial Results

REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating virtually in the upcoming BofA Securities 2021 Healthcare Conference.

Seer to Present at the BofA Securities 2021 Healthcare Conference

REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 10, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report First Quarter Financial Results on May 10, 2021

Seer's (SEER) CEO Omid Farokhzad on Q4 and Full Year 2020 Results - Earnings Call Transcript

Seer Proteograph™ Product Suite combined with SCIEX mass spectrometry technology to provide unbiased, deep proteomics workflows for labs of all types Seer Proteograph™ Product Suite combined with SCIEX mass spectrometry technology to provide unbiased, deep proteomics workflows for labs of all types

Seer and SCIEX Sign Commercial Agreement to Offer End-to-End Unbiased Proteomics Solutions

Added Salk Institute as collaboration customer and SCIEX as new commercial partner Added Salk Institute as collaboration customer and SCIEX as new commercial partner

Seer Reports Fourth Quarter and Full Year 2020 Financial Results and Fuels Commercial Progress in 2021 with New Collaborators and Partnerships

REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 29, 2021. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Seer to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021

Applied Materials

FleetCor Technologies

MGM Resorts

Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the fourth quarter of 2020, which ended on Dec. 31.

Top 4th-Quarter Buys of Lee Ainslie's Maverick Capital

REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.

Seer to Present at the Cowen 41st Annual Healthcare Conference

REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten public offering of 3,750,000 shares of Class A common stock at a public offering price of $67.00 per share, before deducting underwriting discounts and commissions. Of the 3,750,000 shares sold in the offering, 1,650,000 were sold by Seer and 2,100,000 were sold by selling stockholders of Seer.

Seer Announces Closing of Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the pricing of an underwritten public offering of 3,750,000 shares of Class A common stock (1,650,000 of which are being offered for sale by Seer and 2,100,000 are being offered for sale by selling stockholders of Seer) at a public offering price of $67.00 per share. In addition, the selling stockholders of Seer have granted the underwriters a 30-day option to purchase up to 562,500 additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 1, 2021, subject to satisfaction of customary closing conditions. Seer will not receive any proceeds from the sale of shares in the offering by selling stockholders.

Seer Announces Pricing of Upsized Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the commencement of a proposed underwritten public offering of 3,500,000 shares of Class A common stock (1,400,000 of which are being offered for sale by Seer and 2,100,000 are being offered for sale by selling stockholders of Seer). In addition, the selling stockholders of Seer expect to grant the underwriters a 30-day option to purchase up to 525,000 additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Seer Announces Proposed Public Offering of Common Stock

Combination of Thermo Fisher's market leading Orbitrap mass spectrometer portfolio with Seer Proteograph™ Product Suite to expand availability of end-to-end proteomics in new markets Combination of Thermo Fisher's market leading Orbitrap mass spectrometer portfolio with Seer Proteograph™ Product Suite to expand availability of end-to-end proteomics in new markets

Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics

REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

News for Seer Stock (SEER)